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ABSTRACT 
 
The development of Next-Generation Sequencing (NGS) technologies has 
added a new method to investigate the role of genes in several diseases, 
including breast cancer (BC). For example, RNA-Seq is mainly used to 
analyze the continuously changing cellular transcriptome and finding the 
pathways enriched/inhibited by the differently expressed genes. Small RNA-
Seq is a very similar method allowing the detection of other classes of RNA 
such as small non-coding RNA (miRNA, piRNA, tRNA). In particular, 
microRNAs (miRNA) are a small non-coding RNA that regulate gene 
expression at the post-transcriptional level by binding to the 3'UTR 
(untranslated region) of target mRNAs, causing their degradation or 
translation inhibition. Several studies correlated an altered expression of 
these sncRNAs with the onset and /or progression of different diseases, 
including cancer. They can be used as biomarkers, playing a key role in the 
diagnosis, prognosis and prediction of response to specific therapies. 
Moreover, many studies have focused on the possibility of developing new 
therapeutic strategies based on microRNAs modulation and their potential 
use in the personalized management of cancer. Furthermore, also Piwi-
interacting RNA (piRNA) is a class of small non-coding RNA molecules 
expressed in animal cells that are associated with both epigenetic and post-
transcriptional gene silencing of retrotransposons and other genetic elements. 
They are distinct from miRNA in size (26–31 nt rather than 21–24 nt), lack 
of sequence conservation, and increased complexity. The aim of my research 
project was to understand the carcinogenic mechanisms and pathways 
modulated by these mRNAs and smallRNAs, since the clarification of the 
roles played by these molecules in cancer might provide new opportunities to 
develop novel strategies for diagnosing and treating this disease using 
bioinformatics tools and created it. Furthermore, a tool has been created that 
allows the analysis of smallRNAs by integrating various software to facilitate 
the use of this technology and to better explore the expected results. 
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1. INTRODUCTION 
 
Fifteen years ago the Human Genome Project (Human Genome Project) was 
completed and from there on research on genomes structure and functions 
made a significant step forward. This was possible thanks to the significant 
developments in the field of sequencing technologies of DNA, whereby from 
the ‘Sanger’ DNA sequencing technique, which untill that time was the 
standard approach, we moved on to the, so-called, Next-Generation 
Sequencing (NGS), based on massive parallel sequencing technologies. 
Today, the human genome can be sequenced in less than a week and soon, 
systematically, down to a couple of days. NGS has allowed remarkable 
advances in the new era of biology, known as "post-genomics", leading to a 
greater understanding of how, where and when all genes of a given cell or 
tissue are regulated, allowing to gather a great amount of data in a single 
experiment, with significantly lower costs compared to past. This global 
approach to science has been successfully applied to different areas of 
research and led to the birth and development of a new set of disciplines, the 
so-called "-omics", such as transcriptomics (study of the transcriptome), 
proteomics (study of the proteome), interactomics (study of the interactions 
between the products of multiple genes), cellomics (studies of cellular 
functions and impact of drugs at the cell level), genomics (large-scale 
molecular analyzes of a set of genes, on gene products or on regions of 
genetic material) and miRNomics (study of miRnoma), each of these 
stimulating in turn the development of new ones technologies to facilitate 
work. 
 
1.1 New Methods for Genomic Analysis  
 
Traditional techniques for coding and non-coding RNA analysis represent a 
limited approach for the study of genomes, because they generally focus on a 
single gene at a time or on a limited set of them. The advent of Next-
Generation-Sequencing has marked a remarkable and important step forward 
for this field. The global approaches developed, such as the RNA-Seq and 
smallRNA-Seq, have allowed, in fact, to investigate more in depth and at 
lower costs, the complex interactions between DNA and proteins and the role 
played by regulatory transcripts. This progress has also been made possible 
by the parallel development of methods for data analysis that tries to make 
the interpretation less problematic. RNA-Seq is used to analyze the 
continuously changing cellular transcriptome, it is used for look mRNA gene 
splicing, gene fusion and change in gene expression. RNA-Seq also allows 
other classes of mRNA like long non-coding RNA and small non-coding 
RNA. In particular, micro RNA is a small non-coding RNA that regulate 
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gene expression at the post-transcriptional level by binding to the 3'UTR 
(untranslated region) of target mRNAs, causing their degradation or 
translation inhibition. Piwi-interacting RNA (piRNA) is a class of small non-
coding RNA molecules expressed in animal cells that are linked to both 
epigenetic and post-transcriptional gene silencing of retrotransposons and 
other genetic elements. 
 
1.2 microRNA (miRNA)  
 
miRNAs were first identified in the 1993s with the discovery of let-7 and 
Lin-4 in a worm (Caenorhabditis elegans) and after the presentation of this 
small RNA was detected in multiple eukaryotic organisms and mammalian 
species (Lagos-Quintana et al., 2001). They play an important role in the 
modulation of biological processes through the regulation of gene expression 
in a post-transcriptional manner, primarily by binding to the 3’ untranslated 
region (3’UTR) of messenger RNAs and resulting in a down-regulation of 
target proteins through the degradation of these mRNAs or by translation 
inhibition. The miRNA-RISC complex can block translation of target 
mRNAs into protein and/or induce degradation of target mRNA transcripts 
(Bartel et al., 2009) (Figure 1.1). The binding between miRNA and its target 
messenger happens through the complementarity of bases; in mammals, the 
complementarity in most of the cases is partial and determines a translation 
of the block while the total complementarity (especially in plants) occurs 
only rarely and induces degradation of the transcript. miRNAs can modulate 
about 30% of protein-coding genes in humans (Lewis et al., 2005). 
 
 
 
Figure 1.1: miRNAs biogenesis: Several stages in miRNAs maturation started in the nucleus after 
transcription in pri-miRNA and ended in the cytoplasm by RISC complex (from Spadaro et al, 2012) 
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1.3 Piwi-interacting RNAs  
 
Of the other smallRNAs, piRNAs are the least studied and analyzed. One role 
of piRNAs in germline cell is protect from the double-stranded breaks and 
insertional mutagenesis caused by active transposons. Derived from long, 
single-stranded RNAs, nearly all of which are shockingly long and 
transcribed from genomic ‘clusters'—transposon-rich regions of the genome 
thought to record the waves of transposon invasions survived by an animal 
and its evolutionary forebears (Vagin et al., 2013). How show in figure 1.7, 
piRNA precursor transcripts are fragmented and perhaps trimmed to yield 
primary piRNAs; primary piRNAs initiate an amplification loop (the ‘ping-
pong' cycle) that generates secondary piRNAs; and, finally, the resulting 
amplified piRNAs silence their regulatory targets, such as the mRNA 
transcripts of transposons, by guiding a specialized sub-class of Argonaute 
proteins. These specialized Argonaute proteins are called PIWI proteins, after 
the founding member of the sub-family, the Drosophila protein, P-element-
Induced Wimpy Testes or Piwi (Lin and Spradling, 1997).  
 
 
 
 
Figure 1.2: Biogenesis of piRNAs in the germline and in somatic follicle cells. In the germline, 
piRNAs are generated through an Aub- and Ago3-dependent piRNA amplication cycle, whereas in 
somatic cells, biogenesis occurs through a Piwi-dependent, Aub- and Ago3-independent pathway (from 
Zamorea, 2010). 
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1.4 Breast Cancer 
 
Breast cancer (BC) is the second cause of cancer death in women aged from 
20 to 59 years, with 29% of new cancer diagnoses in the female population 
worldwide. Breast tumor occurs after pre-pubertal age with an incidence that 
increases after the third decade of life up to 60 years (Siegel et al., 2016). 
This cancer is manifest in the mammary gland, an exocrine glandular tissue, 
responsible for lactation, characterized by modified apocrine secretion and 
controlled by reproductive hormones.15 to 29 lobes that are segregated in 
stroma by adipose and connective tissue form it. The lobes are divided into 
smaller lobules joining up with the alveoli and each lobule has a lactiferous 
duct that drains into openings of the nipple. When cancer is discovered, 
microscopic analysis of breast tissue is necessary for a definitive diagnosis to 
characterize the histotype of disease. The tissue for microscopic analysis is 
usually obtained via a needle or surgical biopsy. BC generally originates in 
the epithelium of glandular ducts and lobules, namely respectively ductal or 
lobular adenocarcinoma; the first is most of the cases. BC can be classified as 
in situ or invasive carcinoma. They originate from the duct-lobular terminal 
(TDLU, Terminal Duct Lobular Unit) and, while in situ BCs are 
characterized by the proliferation of atypical epithelial elements within the 
lobules and ducts but without overcoming their basement membrane, the 
invasive form, representing the most advanced form of cancer, are 
distinguished by their acquired metastatic skill (Pontieri et al., 2005). Further 
classification takes into account the histological features, distinguishing 
seven different groups among the invasive carcinomas (American Cancer 
Society, 2015). The classification of BC has requested the development of 
several techniques of analysis given its heterogeneity, encompassing multiple 
tumor entities, each characterized by distinct morphology, behavior and 
clinical implications. Immunohistochemistry (IHC) classified BCs by their 
anatomical and molecular features, in particular the presence of the Estrogen 
Receptor alpha (ERα, a well-established diagnostic and prognostic marker) 
into ER-positive (hormone-responsive tumor) and ER-negative categories. 
Today, high throughput proteomics and gene-expression profiling methods 
are being explored as diagnostic tools. The study to examine comprehensive 
gene-expression patterns in human BC have identified 4 subtypes (basal-like, 
HeR2, normal breast-like and luminal) (Perou et al., 2000) and their 
association to the classical tumor classification led to a better diagnosis of the 
disease (Sotiriou et al., 2003; Sorlie et al., 2001). The common cause of 
hereditary BC is an inherited mutation in the BRCA1 and BRCA2 genes (5% 
to 10% cases of BC), involved in DNA reparation. These mutations can act 
bind with mutations in key genes of cell proliferation and survival, such as 
p53, PTEN, ATM, typical of neoplastic transformation of the cells (Robbins 
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e Cotran, 2006). BC is associated with several risk factors divided into 
genetic and environmental factors. The environmental factors are the lifestyle 
(abuse of alcohol, smoking, high fat consumption in the diet), the geographic 
area, exposure to radiation and to infectious agents, even if the most 
important factor is the prolonged exposure to estrogenic stimulation like 
endogenous and exogenous (Platet et al, 2004). For normal development of 
the mammary gland the estrogen signal is essential and a deregulation of this 
pathway is responsible for tumor progression. 70% of the BCs are hormone-
responsive and express ERα. 
 
1.5 GAPT2 role in BC 
 
The first step in glycerolipid biosynthesis is catalyzed by Glycerol-3-
phosphate acyltransferase (GPAT), in which glycerol-3-phosphate is acylated 
to form lysophosphatidic acid. Four isoforms are known such as GPAT1–
GPAT4 and have been described which differ in their subcellular location, 
tissue expression pattern, substrate preference, transcriptional regulation, and 
sensitivity to sulfhydryl group reagents such as N-ethylmaleimide (Gonzalez-
Baro et al., 2017). GPAT2 is a mitochondrial isoform that is highly expressed 
in the testis, where its expression is transient, being restricted mainly to 
primary spermatocytes (Cattaneo et al., 2012). Although GPAT2 was initially 
associated with lipid metabolism a recent work links GPAT2 to the 
biogenesis of Piwi-interacting RNAs (piRNAs) (Shiromoto et al., 2013). 
piRNAs are a class of small non-coding RNAs (sncRNAs) of 24-31 nt in 
length that function in germline cells to silence retrotransposons and maintain 
genome integrity (Iwasaki et al., 2015). GPAT2 knockdown in MDA-MB-
231 BC cells diminished cell proliferation, anchorage-independent growth, 
migration and tumorigenicity, and increased staurosporine-induced apoptosis. 
In contrast, GPAT2 over-expression increased cell proliferation rate and 
resistance to staurosporine-induced apoptosis (Pellon-Maison et al., 2014). 
 
1.6 DOT1L and BC 
 
Based on hypothesis, the molecular partners of ERα involved in the 
multiprotein complexes that it requires for its transcriptional activity, 
including epigenetic regulators, represent potentially exploitable targets for 
new therapies against ER positive and antiestrogens-resistant tumors. For 
proteomic interaction we identified histone methyltransferase DOT1L 
(Disruptor of telomeric silencing-1-like) as a component of multiprotein 
complexes that assemble with ERα in the nuclei of BC cells after estrogen or 
anti-estrogen treatment. DOT1L catalyzes mono-, di- and tri-methylation of 
histone H3 on lysine-79 (H3K79me), a marker of transcriptionally active 
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genes, and is involved in transcription elongation, DNA repair and cell cycle 
progression. This enzyme is associated with the mystical leukemia fusion 
protein (MLL) and plays a key role in the transcription mechanisms that 
support leukemogenesis, and for this reason its inhibitors have been 
proposed, and clinically tested, as therapeutic targets for leukemia by MLL 
merger. The role and functional significance of the DOT1L association with 
ERα in hormone responsive human BC cell nuclei have been studied here in 
detail. The results demonstrate the co-recruitment of both factors, in 
combination with other transcriptional epigenetic regulators, into a 
considerable fraction of ERα -CM-7 cell chromatin, thus influencing the 
transcription of genes involved in key cellular functions, including ESR1 
(encoding ERα), FOXA1 and other ERα co-regulators. These results 
demonstrate for the first time that DOT1L represents a novel molecular target 
for epigenetic therapies against endocrine-responsive and ER-positive, 
hormone-resistant mammary carcinomas. 
 
1.7 Colorectal cancer and LINE-1 transposable elements 
 
Colorectal tumors present with a series of genomic and epigenomic 
alterations through interactions between neoplastic cells, immune cells and 
microbiotics. In particular, the hypo-methylation status of the long nucleotide 
nucleotide element-1 (LINE-1), which constitutes about 18% of the entire 
human genome, has been associated with a greater chromosomal instability 
that may cause a low antitumor immunity level in colorectal cancer (Gaudet 
et al., 2003). In fact this hypomethylation involves a lower density of T cells 
in the tumor tissue and a worse clinical outcome (Ogino et al., 2008). Other 
studies have shown that the prognostic association of the methylation level of 
the LINE-1 tumor with microsatellite instability (MSI) (Rhee et al., 2012). It 
should also be noted that this instability may be sporadic or hereditary, taking 
the name of Lynch syndrome. In species such as Drosophila and mouse, the 
silencing of the Transposable Elements (TE) is performed by piRNAs; in the 
special case of mice, MIWI2 is necessary in germ cells for the determination 
of CpG methylation status on genome sequences of transposons (Aravin et 
al., 2008). Furthermore, piRNAs have also been implicated in silencing the 
LINE1 in human tumor lines. 
 
1.8 Pancreatic cancer and Annexin A1 
 
Recently, the oncogenic role of Annexin A1 (ANXA1) has been found in 
pancreatic cancer (PC), where protein expression is directly related to the 
poor prognosis of patients (Chen et al., 2012). It has also been shown that 
ANXA1 improves cell migration and invasion by acting both directly in the 
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intracellular compartment and indirectly through interaction with formyl 
peptide receptors (FPRs, Belvedere et al., 2012). In addition, the knock-out 
ANXA1 (KO) in our in vitro model using the CRISPR/Cas9 genome editing 
system on PC MIA PaCa-2 cells revealed the deregulation of a large number 
of proteins involved in the organization of cytoskeleton. This led to reversion 
of the epithelial-to-mesenchymal transition (EMT), leading to a less 
aggressive phenotype. Lately, the study of the miRNA profile has been found 
useful as a diagnostic screening method also for PC, where, among the most 
characterized miRNAs, miR-196a has been associated with recurrence and 
shorter survival (Kong et al., 2012). miR-196a is considered a discriminating 
factor between PC and normal pancreas, because it is upregulated only in 
tumor samples (Wang et al., 2009). Furthermore, in vitro it has been 
demonstrated that miR-196a has an expression profile directly correlated to 
the aggressiveness of PC cells, as assessed by EMT (Gaianigo et al., 2017). 
Understanding the molecular mechanisms of ANXA1 in cancer also implies 
the study of its relationship with miRNAs. In fact, the protein can regulate 
downstream gene activation and transcription factors and, on the contrary, 
can be regulated by these. 
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2. AIM 
 
This thesis project has consisted in three main parts: 
1. To develop a tool, named iSmaRT (Small RNA Tool-kit 
integrative), simply to use and to investigate the biological roles of small 
non-coding RNAs (sncRNAs). It will also be tested on various data including 
Huntington disease and several BC cells; 
2. To apply iSmaRT on trancriptomics data from pancreatic cancer 
MIA PaCa-2 cells carrying ANXA1 ‘knock-out’ (ANXA1ko); 
3. To carry out analysis of patient-derived colorectal cancer 
transcriptomics data from samples classified according to the level of 
methylation of the LINE1, microsatellite instability and the presence of the 
Lynch syndrome. 
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3. MATERIALS AND METHODS 
 
iSmaRT 
iSmaRT is a pipeline, wrote in Python and developed in a virtual machine, 
that integrates several third-party software widely used for the analysis of 
smallRNA-Seq data with own algorithms. sRNAbench (Rueda et al., 2015) is 
the core of iSmaRT, for its capability to detect several classes of sncRNAs, 
being used to perform the main analytical steps required. iSmaRT first 
conducts quality control and filtering of the sequence reads using FASTQC 
(http://www.bioinformatics.Babraham.ac.uk/projects/fastqc/), while Cutadapt 
(Martin, 2011) or sRNAbench are used to remove the adapter sequences and 
low quality reads. Differential expression analysis is performed in iSmaRT 
integrating three Bioconductor statistical packages: DESeq2 (Love et al, 
2014), edgeR (Robinson and Smyth, 2008) and NOISeq (Tarazona et al., 
2015). A novel piRNA prediction method was integrated into the tool-kit, 
working on 25–36nt-long reads filtered out from other classes of sncRNAs 
and using an algorithm based on k-mer scheme (Zhang et al., 2011). The 
enrichment analysis of Gene Ontology terms on miRNA and piRNA RNA 
targets is performed using the R Bioconductor package TopGO (Alexa and 
Rahnenfuhrer, 2010) and pathway analysis is performed by ReactomePA (Yu 
and He, 2016). iSmaRT includes also a module for the identification of RNA 
editing events, comprising REDItools (Picardi and Pesole, 2013). 
 
GPAT2 silencing 
For human GPAT2 silencing, MDA-MB-231 cells were transfected using 
Lipofectamine 2000 Reagent (Life Technologies) with HuSH-29 plasmid 
(OriGene) coding for shRNA against human GPAT2 mRNA and selected 
puromycin resistance to generate the respective silenced MDA-MB- 231 cell 
line (SH). A non-effective scrambled sequence shRNA plasmid was used to 
create a negative control (SC). Both plasmids also contain a sequence coding 
for green fluorescent protein driven by a CMV promoter. 
 
Small RNA sequencing library 
Total RNA was extracted from the cell line using the standard RNA 
extraction method with QIAIzol (Qiagen), quantitated with NanoDrop-1000 
spectrophotometer (Thermo Fisher Scientific) before integrity assessment 
with an Agilent 2100 Bioanalyzer (Agilent Technologies). For small RNA-
seq, 1 μg of total RNA from SH and SC cells was used for library preparation 
with Illumina TruSeq small RNA sample preparation Kit. Three independent 
experiments (two clones per cell line) for each condition, were sequenced (10 
pM) on HiSeq2500 (Illumina) with single read for 51 cycles. Small RNA 
sequencing data was analyzed using iSmaRT (Panero et al., 2017) to identify 
Small non-coding RNAs and cancer: a bioinformatics approach 
 
13 
 
the sncRNA families studied, i.e. miRNAs (miRBase v21), piwi-interacting 
RNAs (piRNABank), and tRNA-derived fragments (tRF, Human genome 
assembly, GRCh37/hg19) with Minimum Read Count of 3. Rfam and 
RefGene correspond to reads mapped to Rfam (Nawrocki et al. and Refgene 
(known human protein-coding and non-protein-coding genes) databases. 
 
Bioinformatics analysis smallRNA-Seq 
To identify differentially expressed miRNAs, piRNAs or tRF between SH 
and SC samples, we used iSmaRT for all the preprocessing of raw file and 
DESeq2 algorithm based on the normalized number of counts mapped to 
each sncRNA transcript (Love et al, 2016). Functional enrichment analyses 
were performed using the databases DAVID, http://david.abcc.ncifcrf.gov/), 
Enrichr (HTTP://amp.pharm.mssm.edu/Enrichr/) and FunRich 
(www.funrich.org), based on the list of genes associated with the deregulated 
sncRNAs (P-adj. ≤0.05; FC ≥|1.5|). Data integration, heatmap visualization of 
differentially expressed transcripts and functional enrichment plots were done 
with R/Bioconductor packages and the Multi Experiment Viewer software 
(MeV v4.9) (Saeed et al., 2003). To validate the bioinformatic analysis of 
small RNA-seq experiments, we compared the global miRNA expression 
profile of SC from our study with the global miRNA expression profile of the 
MDA-MB-231 and MCF10 cell lines obtained from the study of (Zhou et al., 
2014), in which the authors profiled the cellular small RNAs isolated from 
these two cell lines by Solexa deep sequencing. Briefly, normalized data 
were downloaded from GEO (ID#GSE50429) and the miRNAs in common 
to our libraries were selected (n=228). The comparison was made using a 
linear regression model in R. The name or GenBank ID, chromosome 
number, genomic position, strand orientation and sequence length of piRNAs 
was obtained from piRNAbank 
(http://pirnabank.ibab.ac.in/simple_search.html), and validated with the 
NCBI Nucleotide Database (https://www.ncbi.nlm.nih.gov/nuccore/). The 
number of copies in the genome and the genomic loci was obtained from the 
UCSC Genome Browser. To identify potential target genes of relevant 
piRNAs, we employed the NCBI database (Human Genomic plus Transcript) 
based on sequence complementarity using the reverse complement of the 
piRNA sequence as input. The HomoloGene tool from the NCBI database 
was employed to evaluate the grade of conservation of the selected putative 
mRNA targets among different mammalian species. For miRNA target 
prediction and functional annotations, we used the miRDB online resource 
(http://www.mirdb.org/miRDB/). To evaluate differences in the abundance of 
each species of tRF among the upregulated and downregulated group, we 
used Fisher Test to compare their frequencies with the expected frequencies 
according to the Genomic tRNA 
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database (http://gtrnadb.ucsc.edu/). For the identification of putative proteins 
based on amino acids composition, we employed the AAcompIdent tool 
(http://web.expasy.org/aacompident/). For piRNA and snoRNA expression 
levels across human tissues and cell lines, we employed the DASHR database 
(http://lisanwanglab.org/DASHR/smdb.php). To evaluate and compare 
differentially expressed miRNAs found in this study with miRNAs 
deregulated in BCs, we used the YM500v3 database 
(http://driverdb.tms.cmu.edu.tw/ym500v3) which employ TCGA data to 
contrast normal vs cancer tissue. We selected the comparison of 1096 
primary solid tumors against 104 samples of normal breast tissue (Chung et 
al., 2017). Survival section of YM500 database was employed to survival 
analysis of commonly deregulated miRNAs. 
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4. RESULTS 
 
4.1 Part One: Development and testing of iSmaRT tool 
 
Developing tools 
 
A challenging problem in NGS is the choice of the correct strategy to analyse 
the experimental data. SmallRNA-Seq analysis, for example, need different 
bioinformatics software and the possibility to perform multiple, subsequent 
file format conversions that slows-down and makes cumbersome the 
analytical procedure. For this reason, it was decided to design a tool that 
allows the use of graphic interfaces and various homemade scripts to solve 
the problems mentioned above. We will also use various third-party software 
in both standalone and web-based versions. In addition, implementing 
different statistical approaches for sncRNAs expression analyses allows users 
to compare and select the most appropriate method to analyze of their data.  
 
iSmaRT pipeline 
 
iSmaRT is an analytical pipeline, written in Python and R. It can be installed 
with bash script or it can be used running a virtual machine, that integrates 
several third-party software widely used for the analysis of smallRNA-Seq 
data. The workflow of iSmaRT covers several analytical steps with multiple 
programs, that can also be used independently (Figure 4.1). 
 
 
 
 
Figure 4.1: iSmaRT work-flow. 
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All these tools can be used by a Graphical User Interface (GUI)  that allows 
the user to choose different parameters. The tool sRNAbench (Rueda et al., 
2015) is the core of iSmaRT and it is used to perform the main analytical 
steps. iSmaRT starts with the execution of FASTQC in order to perform a 
quality control of the sequencing. Cutadapt (Martin, 2011) or sRNAbench 
can be used to remove the adapter sequences and low quality reads. iSmaRT 
allows to define different libraries to remove all the unwanted reads from the 
next steps of the analysis. iSmaRT can generate different plots, such as those 
showing read-length distributions for each of the sncRNA selected by the 
user, or Principal Component Analysis (PCA) results and heatmaps with 
different distance metrics. iSmaRT can also perform a differential expression 
analysis since it integrates three Bioconductor statistical packages: DESeq2 
(Love et al, 2014), edgeR (Robinson and Smyth, 2008) and NOISeq 
(Tarazona et al., 2015). In recent studies, germline piRNAs have been 
detected also in somatic cells, highlighting the importance of identifying 
specific piRNAs in mammalian somatic tissues, where their exact number 
and functional roles still remain to be elucidated (Ross et al., 2014). To 
address this issue, we integrated in iSmaRT two features that can help 
researchers to address this issue. The first one is the integration of an 
algorithm based on k-mer scheme (Zhang et al., 2011) to select the putative 
new piRNAs from the sequences that are not annotated in the genome. This 
provides a way to identify novel somatic piRNAs that can then be further 
studied. The second one, as increasing evidence suggests that piRNAs are 
able to drive degradation of certain RNA targets via a miRNA-like 
mechanism that operates by imperfect base-pairing rules (Zhang et al., 2015), 
is the implementation of the approach proposed by these Authors to identify 
potential piRNA targets. The enrichment analysis of Gene Ontology terms on 
miRNA and piRNA RNA targets is performed using the R Bioconductor 
package TopGO (Alexa and Rahnenfuhrer, 2010) and pathway analysis is 
performed by ReactomePA (Yu and He, 2016), with the possibility to filter 
the list of mRNA targets against a dataset of mRNAs of interest, such as for 
example those expressed in the samples under study. iSmaRT includes also a 
module for the identification of RNA editing events, comprising REDItools 
(Picardi and Pesole, 2013). We analyzed with iSmaRT the smallRNAs 
sequencing data by Hoss et al. (2015), that demonstrated miRNA 
involvement in Huntington’s disease (HD) pathogenesis by comparing their 
expression in the prefrontal cortex from 26 symptomatic HD patients and 36 
healthy controls. We thereby illustrated the performance of iSmaRT in 
providing a detailed analysis of miRNA and piRNA differentially expressed 
and of piRNA-mRNA interactions. 
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iSmaRT main interface 
 
The iSmaRT main interface, shown in Figure 4.2 reproduces the window that 
appears when the tool is opening. Each choice provided corresponds to a 
particular step of the small RNA-Seq data analysis work-flow and opens one 
or more Graphical Interface (GI), that can be called by clicking the 
corresponding button.  
 
 
      
                
 
 
 
Figure 4.2: iSmaRT main interface. 
 
The click on Complete analysis opening an interface where it is possible to 
select input file (Figure 4.3).  
 
 
 
  
 
 
Figure 4.3: iSmaRT input interface. 
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If Cutadapt is selected, a new window will appear (Figure 4.4), where it is 
possible to specify the adapter sequences. 
 
 
 
 
 
 
Figure 4.4: iSmaRT cutadapt interface. 
The new window (Figure 4.5) is divided in four zones. The first one covers 
the "Mandatory Parameters", where is it necessary to specify where to save 
the output data, the path to the database (DB) folder, the fasta (or index) file 
of mature miRNAs, as downloaded from miRBase, and the fasta file of the 
pre-miRNAs hairpin sequences.  
 
 
Figure 4.5 iSmaRT DB and libraries interface
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The "Pre-filtering" panel allows specifying the name of the library file that 
should be used to filter out certain reads. The "Analysis types and library" 
panel allows defining the other small RNA libraries (Libs) on which to 
perform the analysis and the species (hg19 for human). If "noGenome" 
option is selected (False) then all reads are first mapped to the reference 
genome of species selected. Afterward, the genome coordinates of the 
reference small RNA annotation (Libs for miRNAs and other sncRNAs) are 
determined. In next windows (Figure 4.6) you can select several options of 
output like Principal Component Analysis (PCA), Scatter-plots on two 
samples that can be selected from the window, Heatmaps and Read-length 
distribution graphs. In addition, in this section it is possible to select the 
Differential expression analysis, Target predictions on miRNAs or on 
piRNAs and Novel piRNA identification (if the “Novel piRNAs” function is 
selected). If either of the two “Target predictions” functions is selected, it is 
also possible to select “ReactomePA” function analysis. 
 
 
 
 
 
 
 
Figure 4.6: iSmaRT select workflow 
interface. 
 
 
 
 
 
The new window (Figure 4.7) concerns differential expression analyses.  
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Figure 4.7: iSmaRT DE interface. 
 
It is possible to select here the test and control groups on which library 
(miRNA, piRNA, etc.) to perform the analysis and to choose the statistical 
method to be applied (DESeq2, NoiSeq or edgeR). 
 
Output of iSmaRT 
 Commands.txt: This file contains all the line commands launched by 
iSmaRT and, eventually, the error messages; 
 sRNAbench_analysis:  This folder contains all the output of 
sRNAbench, plus a text file (Terminal.txt) where are saved the 
messages printed in the terminal by sRNAbench; 
 FASTQC: This folder contains the output of FASTQC; 
 R_out: This folder contains the output of the R scripts and, 
eventually, the error messages; 
 Tables: This folder contains the tables generated by sRNAbenchDE. 
If the user selected to perform a differential analysis, the sub-folder 
‘name of test group_VS_name of control group’ will contain the table 
generated by sRNAbench and used for the differential analysis; 
 Differential_analysis: This folder contains the results of the 
differential analysis. The first sub-folder indicates the tool used, the 
second contains indication on the test performed e.g. novel_piRNAs, 
test_vs_control, etc.  
The files that can be generated are: 
 tool_name_normalized_counts.txt: Table of normalized read 
counts; 
 tool_name_log2_med_cent.txt: Table of normalized read 
counts transformed in log2 and median centered; 
 tool_name_results_translibs_name.txt: Table of the tool 
results; 
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 tool_name_results_translibs_name_filtered.txt: Table of 
the filtered tool results with the column FC that indicates the 
fold change;  
 heatmap_norm_counts_log2_med_cent.tiff: Heatmap 
generated from the tool_name_log2_med_cent.txt table. 
 Plots: This folder contains sub-folders with the names of the 
translibs analyzed. Each sub-folder can contain the following files: 
 translibs_name.mat: Read counts generated by 
sRNAbenchDE; 
 Heatmap.tiff: Heatmap made using the rlog function of 
DESeq2; 
 PCA.tiff: PCA made using the rlog function of DESeq2; 
 ScatterPlots.tiff: Scatterplots of the read counts; 
 sequencingStat.txt: File generated by sRNAbench. 
 Read_lengths: This folder contains sub-folders with the names of 
the samples. In each sub-folder can be found the folder(s) with the 
name of each translibs analyzed. Each sub-folder can contain the 
following files: 
 sample_name_translib_name.txt: This file contains each 
sequence of the translibs, with its corresponding read counts; 
 frequencies.txt: Read counts of the sequence in the translibs; 
 sample_name.png: Plots of the frequencies. 
 GO: This folder contains the results of the Gene ontology analysis. 
Each sub-folder contains a description of what was tested and the can 
contain the following files (some may be missing if no enrichment 
was found): 
 GO_results.txt: table with the enriched GO terms with the 
associated genes and statistical tests. 
 enrihMap.tiff 
 enrichment_results_barplot.tiff 
 enrichment_results_dotplots 
 novel_piRNAs: This folder contains the results of the analysis for 
piRNA likes and can contain: 
 novel_piRNAs.txt: This file contains the genomic location of 
each piRNA like identified in all samples, and the 
corresponding read counts in each sample. These putative 
piRNAs are named p_id_numeber if they have a single 
location in the genome 
orcp_sequence_id_number_locus_id_number if the 
corresponding sequence have multi-alignment in the genome; 
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 novel_piRNAs.bed: BED file generated using the 
novel_piRNAs.txt information; 
 novel_piRNAs.fa: FASTA file generated using the 
novel_piRNAs.txt information; 
 piRNA_predictor_ERROR_log.txt: This file can contain 
errors or warnings of piRNApredictor, if the file is empty, no 
error/warnings were found/issued by the tool; 
 info: This folder contains a sub-folder for every sample analyzed. 
Each sub-folder contains the files:  
1. novel_piRNAs.txt, novel_piRNAs.bed and 
novel_piRNAs.fa for the piRNA-like identified in each 
sample; 
2. info folder. This folder contains these files: 
 All_Reads.fa: FASTA file of the not assigned 
reads, with new sequence id.  
 sample_name.txt: Read counts of the reads 
contained in All_reads.fa; 
 All_Reads_Table.txt: Tables that contains the 
information found in All_Reads.fa and 
sample_name.txt; 
 predictedpiRNA_ALL_Reads.fa: piRNAs 
predicted by piRNApredictor using as input 
All_Reads.fa; 
 predictedpiRNA_ALL_Reads.bed: BED file of 
predictedpiRNA_ALL_Reads.fa; 
 merge_test.txt: Output of bedtools merge using 
as input predictedpiRNA_ALL_Reads.bed; 
 piRNA_predictor_error_log.txt: This file can 
contain errors or warnings of piRNApredictor, if 
the file is emptied, no error/warnings were 
found/issued by the tool; 
 RNA-editing: This folder contains a sub-folder 
for every sample analyzed. In each sub-folder the 
output of REDItools can be found; 
 Target_predictions: This folder can contain the 
miRNAs, piRNAs and novel piRNAs RNA target 
predictions. For piRNAs and novel piRNA can 
be found also: 
 3UTR_CDS_5UTR.txt: This file contains 
the name(s) of the piRNA(s) or piRNA 
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like(s) with each RNA target and the 
position of targeting (5UTR, CDS or 5UTR); 
 info: This folder contains: 
 3UTR.txt: Bowtie output for the 
alignment in the 3UTR region; 
 CDS.txt: Bowtie output for the 
alignment in the CDS region; 
 5UTR.txt: Bowtie output for the 
alignment in the 5UTR region; 
 nucl.txt: This file contains the first and 
tenth nucleotides of piRNAs or novel 
piRNAs; 
 piRNA_list.txt: List of the piRNAs 
analyzed; 
 piRNA_list_cutted.fa: FASTA file 
‘cutted’ used by Bowtie. 
 
Testing procedure iSmaRT on Huntington’s disease data 
 
The brain smallRNA-Seq datasets has been analyzed using iSmaRT with the 
default parameters. After to have have obtained the miRNAs results obtained 
by the authors we focused on the piRNAs. Considering piRNAs, this allowed 
identification of 2200 such RNAs present in the datasets analyzed. 
Differential expression analysis was performed comparing HD and control 
samples, revealing 16 piRNAs differentially expressed in HD samples. The 
results are summarized in Figure 4.8 and Figure 4.9. 
 
 
 
 
 
 
 
Figure 4.8: miRNAs differentially 
expressed in Huntington 's disease vs 
healthy brain samples. The 
heatmap shows the 45 miRNAs identified 
with iSmaRT as differentially expressed in 
brain samples of Huntington's disease 
(Huntington) patients respect to normal 
(Healthy) individuals. 
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It is worth noting that cluster analysis revealed a meaningful sample 
distribution between the two groups. Novel piRNA prediction allowed 
identification of 40 000 piRNA-like RNAs. To address the potential 
functional impact of the 16 piRNAs found deregulated in HD, we performed 
target prediction, followed by Reactome Pathway enrichment analysis 
(Figure 4.10 and 4.11).  
 
 
Figure 4.9: piRNAs differentially expressed in Huntington 's disease vs healthy brain samples. The 
heatmap shows the 16 piRNAs identified with iSmaRT as differentially expressed in brain samples of 
Huntington's disease (Huntington) patients respect to normal (Healthy) individuals.  
 
 
 
Figure 4.10: Summary of ReactomePA GO analysis performed on mRNAs target of differentially 
expressed piRNA. The barcharts display enriched pathways identified by the ReactomePA of iSmaRT 
in which are involved the mRNAs target of the 16 piRNAs differentially expressed in Huntington's 
disease patients brain. 
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Figure 4.11: enrichMap visualization performed by iSmaRT on mRNAs target of differentially 
expressed piRNA. Enriched pathways in which are involved the mRNAs target of the 16 piRNAs 
differentially expressed in Huntington's disease patient brain. 
This revealed the involvement of several genes encoding piRNA target 
mRNAs involved in pathways related to brain physiopathology, such as for 
example ‘CASP8 activity’ (CFLAR gene, Strand et al., 2005) and 
‘Downregulation of TGF-beta receptor signaling/ Downregulation of 
SMAD2/3:SMAD4 transcriptional activity’ (NEDD4L gene, Ding et al., 
2013). Finally, miRNA and piRNA sequence analysis revealed, for a subset 
of HD samples, the presence of canonical and non-canonical editing events. 
  
Testing procedure iSmaRT on GPAT2 silenced BC cell 
 
To analyze the role of GAPT2 in the biogenesis of piRNAs and the goodness 
of iSmaRT, GPAT2 silencing was performed by shRNA plasmid transfection 
and puromycin selection in the MDA231 cell. From scramble control cells 
(SC) and GPAT2 silenced cells (SH) GPAT2 mRNA expression was reduced 
by 90% and GPAT2 protein was undetectable in SH cells. Silencing GPAT2 
affects sncRNA distribution. Indeed, SC cells, we identified an average of 
67% of miRNAs, 3% of piRNAs, 7% of tRF, 5% of Rfam, 7% of Refgene 
and 11% of non-assigned transcripts, whereas in SH cells, 53% were 
miRNAs, 8% piRNAs, 13% tRF, 4% Rfam, 9% Refgene and 13% not-
assigned transcripts (Figure 4.12). The percentages of total reads for each 
category differed in SC and SH cells, differences were only significant for 
the miRNA category, with a decrease after GPAT2 silencing (Figure 4.12).  
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Figure 4.12: sncRNA distribution in SC and SH cells. Piecharts of the percentages of aligned 
reads assigned to each category of sncRNA in the SC cells and SH cells. A significant decrease was 
observed in the abundance of miRNAs of the SH cells * p-value≤0.05. 
 
 
 
Total piRNAs abundance did not change after GPAT2 silencing, an upper 
shift in reading length distribution was observed (Figure 4.13).  
 
Figure 4.13: Length distribution of reads assigned to piRNAs in SC and SH libraries 
 
 
In SC cells, length distribution was bimodal, with peaks at 27 and 30 nt, 
whereas in SH cells, only one peak at 29 nt was obtained. Differential 
expression analysis shows that of the 137 piRNAs identified in SC cells, 77 
(56%) were differentially expressed after GPAT2 silencing (p≤0.05, 
FC≥|1.5|), with 38 upregulated (28%) and 39 downregulated (28%) (Figure 
4.14). Length distribution shows that piRNAs of 27 and 28 nt in length were 
significantly associated with the downregulated group (p-value ≤0.05). There 
were no differences in the other lengths (Figure 4.14). 
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Figure 4.14: Piechart representation of the percentages of differentially expressed piRNAs and 
barchart of the frequencies of piRNAs in the upregulated and downregulated groups distributed 
according to their nucleotide length.  
 
A lot of the downregulated piRNAs (32/39, 82%) are single copy (p-
value≤0.05), being mainly intragenic (27/32, 84%); whereas in the 
upregulated group, piRNAs with single (18/38, 47%) and multiple (20/38, 
52%) copies showed similar frequencies (p-value≤0.05) (Figure 4.15).  
 
 
 
 
 
 
 
 
 
Figure 4.15: Heatmap representation of 
the differentially expressed piRNAs; the name 
of the host snoRNAs when it corresponds, and 
copies in the genome are indicated. 
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Single copy, upregulated piRNAs however were mostly intergenic (14/18, 
77%, p-value ≤0.05). Indeed, piR-36011, a multiple copy downregulated 
piRNA, maps to the loci of the SNar genes (small NF90-associated RNAs). 
By contrast, none of the upregulated piRNAs is hosted in a SNOR or SNAR 
gene. Moreover, snoRNAs constituted the host gene of 22 out of 27 (81%) 
intragenic single copy downregulated piRNAs, which is 56% of all 
downregulated piRNAs, with a probability value ≤0.05 when compared with 
the upregulated piRNAs. Certain piRNAs are derived from snoRNAs 
precursors (Taft et. Al, 2009), and that piRNAs are tissue restricted, now in 
this work has been evaluated whether there is a correlation in tissue 
distribution among the downregulated piRNAs and their hosted snoRNAs. 
For the analysis of the tissue profile of the piRNAs and the host snoRNAs 
that were available in the database we use DASHR. Unsupervised clustering 
based on Pearson correlation was assayed on the nine pairs of 
piRNAsnoRNA obtained from the search. In all cases an almost perfect 
correlation (~1) was shown, coincident with a co-expression pattern (Figure 
4.16). 
 
 
 
 
 
 
 
Figure 4.16: Corrplot of the pairs 
piRNA-snoRNA. 
 
Four of the top-five upregulated piRNAs previously identified in BC cells 
(Hashim et. Al., 2014), was found downregulated in the SH cells (piR-31636, 
piR-57125, piR-35548 and piR-57125). piR-36041 and piR-43772 which 
were markedly downregulated in MCF7 growing cells, were found 
upregulated in the SH cells. Furthermore, of the latter group, piR-36743, piR-
36318 and piR-36249 were previously found underexpressed in BC tissues 
compared to their normal counterparts (Hashim et al., 2014). The less 
proliferative phenotype of the SH cells agrees with all these data. Expression 
of four representative piRNAs is shown in Figure 4.17.  
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Figure 4.17: Boxplots of four 
representative piRNAs differentially 
expressed. NDE: Non-Differentially 
Expressed. 
 
Based on literature evidence that piRNAs would be involved in mRNA target 
repression via imperfect base pairing between the piRNA and the potential 
target (Gou et. Al., 2014), we searched for putative mRNA targets by base 
complementarity for all the differentially expressed piRNAs. The genes 
targets varied considerably for each piRNA, ranging from no-hits to hundreds 
of mRNAs. After filtering we obtained a reduced list of targets with 
functional enrichment of piRNA targets yielded terms mainly linked to lipid 
metabolism that included sphingolipid de novo biosynthesis, peroxisomal 
lipid metabolism and synthesis and interconversion of nucleotide di- and 
triphosphates, among others. The expression of the putative piRNA target 
ACSS3, a gene coding for acyl-CoA synthetase short-chain family member 3, 
was assessed by qPCR; as expected, ACSS3 gene expression decreased by 
90% in SH cells. As mentioned earlier, iSmaRT allows the analysis of t-rna 
also.Total reads assigned to tRF did not change after GPAT2 silencing, 275 
tRF were identified as differentially expressed (FC≥|1.5|, p-value≤0.05), with 
147 tRF downregulated and 128 tRF upregulated. The top 40 deregulated tRF 
annotated according to the corresponding mature tRNA ID (Figure 4.18). 
 
 
 
 
 
Figure 4.18: Heatmap 
representation of the top 40 deregulated 
tRF identified in the comparison SC vs 
SH cells and annotated according to the 
name of the mature tRNA.
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To discover a biological meaning for deregulated tRF, we used the 
classification for tRNAs proposed by (Gingold et al., 2014). The authors 
established the existence of two distinct translational programs that operate 
during proliferation and differentiation, which eventually coordinate the 
supply and demand of tRNAs. Differentiated cells are less proliferative, and 
proliferating cells are typically not terminally differentiated, hence, according 
to the cellular status at which they are expressed, Gingold et al. (2014) 
classified the tRNAs into proliferation and differentiation tRNAs. Using 
Venn diagrams, we observed a significant association (p-value≤0.0001) 
between the subset differentiation tRNAs with the downregulated tRF in our 
analysis, whereas the opposite occurred with the upregulated ones, with a 
strong association (p-value≤0.0001) to the proliferation tRNAs subset (Figure 
4.19) 
 
 
Figure 4.19: Venn diagram of the comparison between the upregulated and downregulated tRF 
with the Gingold classification of tRNAs 
 
With tRNAs differently expressed we then used the CompSite expasy 
database and obtained a list of scored putative proteins. Functional 
enrichment of these proteins enabled us to identify the biological processes 
previously associated to GPAT2, such as phosphatidic acid biosynthesis, 
phospholipid acyl chain remodeling and regulation of cell death, among 
others (Figure 4.20). 
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Figure 4.20: Functional enrichment of the putative proteins obtained from the (tRF)-amino acid 
frequencies.  
 
In contrast to piRNAs and tRF, miRNAs abundance significantly decreased 
after GPAT2 silencing (Figure 4.21 and Figure 4.22). Unsupervised 
hierarchical clustering analysis of differentially expressed miRNAs 
demonstrated a clear segregation of SC and SH cells (Figure 4.21). 
 
 
 
 
 
 
 
 
 
Figure 4.21: Heatmap representation 
of deregulated miRNAs in SC vs SH cells. 
 
Statistical analysis revealed 213 transcripts differentially expressed (109 
upregulated & 104 downregulated) between the two cell line conditions. For 
this work we choose miR-5100 and miR-34 to validate small RNAseq data. 
Semiquantitative RT-PCR experiment demonstrates that, as expected, 
premiR-5100 was upregulated whereas pre-miR-34 was downregulated in SH 
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cells. Now we using miRDB, to predict putative targets, and the 50 best 
ranked putative targets for each deregulated miRNA were selected. By pivot 
tables (cross tabulations), the more relevant targets present in at least 5 
miRNAs (>5%) were extracted. This means to select the genes that constitute 
targets for more than five miRNAs. Two lists of putative gene targets were 
obtained, one of 51 genes for the upregulated miRNAs, and the other of 109 
genes for the downregulated miRNAs. To identify biological processes 
associated with miRNA targets, functional enrichment analysis using 
ENRICH database was performed. Pathways analysis revealed specific terms 
associated with mitochondrial biogenesis and IGF1R signaling for genes 
associated with upregulated miRNAs, and oxidative metabolism of lipids and 
lipoproteins for genes associated with downregulated miRNAs (Figure 4.22). 
Among the putative genes targeted by the upregulated miRNAs were APPL1 
and SPRED1, both play critical roles in cell proliferation (Mao et al., 2006; 
Pasmant et al., 2015). 
 
 
 
 
 
 
 
Figure 4.22: (B) Functional 
enrichment of the targets of up-
regulated miRNAs (red) and 
downregulated miRNAs (light blue). 
 
Finally, to discover the impact of deregulated miRNAs on the survival of 
patients with BC, we performed an analysis using the YM500 database. 
According to YM500 there are 226 miRNAs differentially expressed between 
BC tumors (n=994) and normal breast (n=103). We compared this group with 
the 213 deregulated miRNAs identified in our study. We used the normal 
approximation to the binomial distribution as previously described (Smid et. 
Al., 2003) to calculate whether the number of deregulated miRNAs derived 
from each cross-platform comparison was of statistical significance. We 
found sixty-five miRNAs common to both groups (p-value≤0.05, Figure 
4.23). 
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Figure 4.23: Comparison of 
differentially expressed miRNAs in SC 
vs SH cells with differentially expressed 
miRNAs in normal vs breast tumors 
indicates a significant association. Venn 
diagrams of opposite groups (Up vs 
Down) also showed a significant. 
 
Of the 65 miRNAs, 45 are upregulated and 20 downregulated in YM500 BC 
tumors, while 36 and 29 are upregulated and downregulated, respectively, in 
the SH cells from our analysis. We discover a significant association between 
the miRNAs upregulated in breast tumors with the miRNAs downregulated 
in the SH cells (22 miRNAs in common, p-value≤0.05), over between the 
miRNAs downregulated in BC tumors and the upregulated in the SH cells 
(13 miRNAs in common, p-value≤0.05, Figure 4.23). We found that 9 of the 
22 miRNAs that are downregulated in the SH cells have a significant impact 
on BC patient survival if they are upregulated in tumors; whereas only 2 of 
the 13 upregulated miRNAs in the SH cells showed poor prognosis. Figure 
4.24 shows the Kaplan Meier curves of 6 of the 9 miRNAs downregulated 
after GPAT2 silencing and upregulated in breast tumors.  
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Figure 4.24: Kaplan-Meier survival 
curves of BC patient survival of six 
miRNA. We then found miRNAs that are 
downregulated in the SH cells have a 
significant impact on breast cancer patient 
survival if they are upregulated in tumors; 
   
 
Moreover, considering that MDAMB-231 cells are negative for hormone 
receptors, we performed the survival analysis on a defined group of ER- and 
PR-negative breast tumors (n=218) for each of the significant miRNAs 
identified in the comparison normal vs tumor, but no significant association 
with overall survival was found in any of the miRNA analyzed.  
 
Testing procedure iSmaRT on BC cell with EPZ a DOT1L inhibitor 
 
To investigate the functional significance of the ERα-DOT1L interaction in 
BC cell nuclei, estrogenstimulated cells were treated with the selective 
DOT1L inhibitor EPZ004777 (EPZ) on MCF7 cells. Analysis of miRNAs 
was performed with iSmaRT using using as cutoff parameters FC> = | 1.5 | 
and pval <= 0.05. In the case of cell treatment with EPZ for 3 days, only 4 
miRNAs changed, in all cases showing an upregulation in expression respect 
to untreated cells (Table 4.1).  
 
 
 
Table 4.1: miRNA DE in EPZ 3g. 
 
On the other hand, with a 6-day treatment, the data changes significantly. 
With these cutoffs we have 36 upregulated miRNAs and 23 downregulated 
miRNA rc_norm_DMSO_3g rc_norm_EPZ_3g Fold-Change pval
hsa-miR-133a-3p 2.91 10.96 3.77 0.037077584
hsa-miR-1538 4.35 19.14 4.40 0.039833103
hsa-miR-548al 1.00 4.91 4.91 0.007889279
hsa-miR-30c-2-3p 1.37 7.70 5.64 0.037251745
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miRNAs. In particular only has-miR-30c-2-3p his present in both condition 
but discordant. 
 
 
 
 
Table 4.2: miRNA DE in EPZ 6g. 
miRNA rc_norm_DMSO_6g rc_norm_EPZ_6g Fold-change pval
hsa-miR-1306-3p 9.89 1.22 -8.08 0.005614476
hsa-miR-30c-2-3p 8.85 1.22 -7.25 0.016545134
hsa-miR-4762-5p 6.60 1.00 -6.60 0.002889501
hsa-miR-6803-3p 8.49 1.63 -5.22 0.024740127
hsa-miR-142-3p 4.40 1.00 -4.40 0.032448753
hsa-miR-6795-3p 4.06 1.00 -4.06 0.029202612
hsa-miR-6862-3p 10.98 2.85 -3.86 0.033365664
hsa-miR-4473 18.72 4.93 -3.79 0.004227637
hsa-miR-6511a-5p 14.47 4.93 -2.93 0.039025164
hsa-miR-6511b-5p 14.47 4.93 -2.93 0.039025164
hsa-miR-219a-5p 14.02 4.96 -2.83 0.049903685
hsa-miR-3679-5p 23.75 9.19 -2.59 0.023602612
hsa-let-7c-3p 43.73 17.24 -2.54 0.001817052
hsa-miR-4638-3p 29.08 11.52 -2.52 0.009176954
hsa-miR-6750-3p 21.87 9.08 -2.41 0.02340518
hsa-miR-95-5p 31.61 14.05 -2.25 0.016872666
hsa-miR-6886-5p 29.40 13.62 -2.16 0.025223209
hsa-miR-365b-5p 79.42 39.50 -2.01 0.010931282
hsa-miR-7-5p 1283.98 773.48 -1.66 0.035913079
hsa-miR-454-5p 977.54 612.45 -1.60 0.002785227
hsa-miR-424-5p 1225.25 778.11 -1.57 0.004976244
hsa-miR-424-3p 537.03 343.94 -1.56 0.005570036
hsa-miR-340-3p 468.03 309.31 -1.51 0.015123091
hsa-miR-489-3p 8427.74 12759.29 1.51 0.003614636
hsa-miR-205-5p 1330.60 2077.03 1.56 0.004288185
hsa-miR-27b-5p 1381.29 2185.77 1.58 0.002413951
hsa-miR-1246 164.28 266.87 1.62 0.005711576
hsa-miR-338-3p 63.99 104.15 1.63 0.013172527
hsa-miR-378a-5p 47.20 76.90 1.63 0.032782012
hsa-miR-326 263.26 430.65 1.64 0.003850568
hsa-miR-504-5p 213.01 350.64 1.65 0.00449435
hsa-miR-143-3p 400.74 694.82 1.73 0.006595452
hsa-miR-27b-3p 336514.89 588440.37 1.75 0.000197463
hsa-miR-218-5p 94.97 166.83 1.76 0.025331602
hsa-miR-335-3p 1174.11 2066.81 1.76 0.000143118
hsa-miR-708-3p 66.04 118.45 1.79 0.01193539
hsa-miR-1287-5p 319.40 574.64 1.80 0.000363817
hsa-miR-199b-5p 41.19 74.29 1.80 0.010585117
hsa-miR-1283 25.26 45.63 1.81 0.048918489
hsa-miR-23b-3p 8082.66 14618.58 1.81 7.20E-05
hsa-miR-512-3p 21.21 38.71 1.83 0.044123495
hsa-miR-708-5p 86.99 160.15 1.84 0.000722596
hsa-miR-147b 31.17 57.46 1.84 0.01797775
hsa-miR-24-1-5p 26.73 51.81 1.94 0.023499753
hsa-miR-363-3p 99.51 200.00 2.01 8.25E-05
hsa-miR-891a-5p 20.04 43.39 2.17 0.008979936
hsa-miR-20b-5p 10.93 23.86 2.18 0.042088296
hsa-miR-184 9.30 22.24 2.39 0.027618344
hsa-miR-221-3p 258.48 620.61 2.40 9.07E-08
hsa-miR-135b-5p 22.07 56.59 2.56 0.000378118
hsa-miR-127-3p 10.95 28.99 2.65 0.006180826
hsa-miR-222-3p 327.10 866.60 2.65 5.90E-10
hsa-miR-570-3p 6.81 20.25 2.98 0.008393601
hsa-miR-320e 3.57 11.10 3.11 0.045043443
hsa-miR-7114-3p 1.00 5.37 5.37 0.002779168
hsa-miR-642a-3p 1.00 5.75 5.75 0.001740819
hsa-miR-34b-5p 1.00 7.44 7.44 0.000258768
hsa-miR-133a-3p 1.44 15.65 10.89 0.000128599
hsa-miR-7641 1.03 16.16 15.74 2.07E-05
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Part Two: Application of iSmaRT on pancreatic tumor. 
 
The silencing of the ANXA1 in pancreatic cancer cells was previously 
assessed using in vitro models of ANXA1ko MIA PaCa-2 cells created using 
the CRISPR/Cas9 genome modification system. To confirm the lack of 
ANXA1 a Western blot was performed confirming the deletion of ANXA1 
with respect to wild type (WT) and PGS MIA PaCa-2 cells. PGS cells were 
obtained by transfecting MIA PaCa-2 WT cells with an empty vector and 
were used as a control, as they behave very similar to the parental cell line. 
iSmaRT was then used to study miRNA change in both conditions.  The 
following PCA (Figure 4.25) shows the difference between samples:  
 
 
 
 
 
 
 
 
Figure 4.25: PCA of pancreatic 
cancer samples. 
 
As reported in the heatmap in Figure 4.26, 19 miRNAs appeared to be 
upregulated and 28 downregulated with the same cutoffs used previously. 
These miRNAs are listed in Table 4.3.  
 
 
 
 
 
 
Figure 4.26: Heatmap representation of 
deregulated miRNAs in ANXA1ko MIA PaCa-2 
cells vs PSG. 
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Several studies have investigated the role of miRNAs in the PC. Many of 
them have focused on miR-196a as a potential marker because it appears to 
be involved in the acquisition of aggression and related to the poor prognosis. 
When we consider the significant low modulation of mR-196a-5p in the 
ANXA1ko MIA PaCa-2 cells, we have transfected the PGS and ANXA1ko 
cells with their mimicry to highlight its role in our system. Initially, we 
performed a wound healing test to test the migratory capacity of the cells. We 
have seen an increase in the migration rate both in PGS and in ‘knock-out’ 
cells.  
 
 
Table 4.3: miRNA DE in ANXA1 KO MIA PaCa-2 cells vs PSG. 
 
This increase appears more evident in the ANXA1ko cells since this clone has 
confirmed that it is characterized by a lower migratory behavior. 
Furthermore, following the same transfection procedures, an invasion test 
was performed through the matrigel lining with PGS and ANXA1ko cells. In 
the presence of miR-196a-5p mimicry, a strong increase in the invasion rate 
of the analyzed clones was observed. 
  
Name log2FoldChange pvalue padj FC PGS1 PGS2 PGS3 B11 D6 G5
hsa-miR-335-3p -3,988886412 5,20E-27 4,55E-24 -15,88 368 429 890 29 21 12
hsa-miR-335-5p -3,499910597 1,26E-13 2,75E-11 -11,31 50 106 241 6 4 0
hsa-miR-196a-5p -3,315893732 2,96E-12 4,32E-10 -9,96 245 107 36 4 2 6
hsa-miR-6510-3p -2,798868925 4,70E-15 1,37E-12 -6,96 135 83 124 15 8 12
hsa-miR-135b-3p -2,701423037 2,10E-15 9,20E-13 -6,50 197 173 177 35 16 12
hsa-miR-34a-5p -2,440875382 2,00E-06 0,000116574 -5,43 10 25 19 0 1 0
hsa-miR-135b-5p -2,420276737 5,53E-11 6,90E-09 -5,35 508 506 482 121 55 30
hsa-miR-205-5p -2,019857469 9,07E-05 0,003773043 -4,06 37 10 4 0 0 0
hsa-miR-4421 -1,9973394 0,000115235 0,004577957 -3,99 11 13 10 0 1 0
hsa-miR-1252-5p -1,899994118 0,000227203 0,007943019 -3,73 22 7 6 0 0 0
hsa-miR-3664-3p -1,79037834 0,000473434 0,01426832 -3,46 23 11 12 1 0 4
hsa-miR-6501-5p -1,621481458 0,001308297 0,032670043 -3,08 16 12 21 2 5 0
hsa-miR-10a-3p -1,558956342 7,04E-06 0,00038447 -2,95 1.188 469 526 270 190 171
hsa-miR-4524a-5p -1,52699932 0,002489867 0,046300932 -2,88 5 14 4 0 0 0
hsa-miR-203a-3p -1,344244283 0,000376896 0,012669507 -2,54 223 356 124 78 108 46
hsa-miR-486-5p -1,309498345 1,85E-08 1,47E-06 -2,48 328.553 222.534 242.884 90.913 94.842 118.640
hsa-miR-10a-5p -1,215868565 0,000459015 0,01426832 -2,32 1.237.694 453.303 459.268 276.480 245.139 295.758
hsa-miR-548f-3p -1,159929075 0,002476268 0,046300932 -2,23 35 32 36 10 13 16
hsa-miR-4461 -1,072940294 0,001408345 0,034191495 -2,10 359 460 188 104 178 151
hsa-miR-3177-3p -1,045932113 0,002360282 0,045841925 -2,06 65 49 50 25 29 17
hsa-miR-10b-5p -1,014936036 0,001930895 0,040181005 -2,02 475 221 214 125 133 155
hsa-miR-589-3p -0,976857478 2,99E-05 0,001450035 -1,97 3.059 2.220 2.558 1.338 1.017 1.477
hsa-miR-2116-3p -0,952462563 0,00098909 0,026195905 -1,94 281 226 176 144 96 92
hsa-miR-584-5p -0,905178961 0,001602456 0,036856499 -1,87 48.437 30.585 29.511 24.624 15.035 15.072
hsa-miR-378e -0,897734504 0,000814801 0,022254239 -1,86 189 275 235 125 93 140
hsa-miR-18a-3p -0,778851246 0,001909198 0,040181005 -1,72 832 654 538 445 317 376
hsa-miR-378d -0,721127459 0,001694498 0,037974123 -1,65 466 633 528 371 286 302
hsa-miR-1275 -0,709818502 0,001553611 0,0366988 -1,64 2.220 2.658 2.262 1.248 1.755 1.252
hsa-miR-1269b 0,626999862 0,001885094 0,040181005 1,54 1.213 1.354 1.512 2.413 1.934 2.063
hsa-miR-15b-5p 0,65674351 0,001073332 0,027590958 1,58 9.158 10.032 7.877 12.664 15.626 15.179
hsa-miR-181a-2-3p 0,840009328 1,77E-06 0,000114476 1,79 2.854 2.753 2.737 5.486 4.645 5.073
hsa-miR-628-5p 0,859023846 0,000657596 0,018539964 1,81 124 184 174 259 315 335
hsa-miR-3912-3p 0,867255438 0,001994361 0,040536541 1,82 40 48 42 86 80 84
hsa-miR-3129-5p 0,899188363 0,000521556 0,015194667 1,87 112 158 98 223 237 257
hsa-miR-3129-3p 0,952049042 0,000165186 0,006277058 1,93 447 320 269 612 724 763
hsa-miR-449a 0,99430699 0,002188548 0,043472522 1,99 59 40 62 160 103 86
hsa-miR-561-5p 1,073417673 0,000445629 0,01426832 2,10 105 244 174 449 390 352
hsa-miR-9-5p 1,281883283 8,35E-05 0,003647348 2,43 297 506 789 1.768 1.197 1.359
hsa-miR-34c-5p 1,32507668 1,83E-06 0,000114476 2,51 260 455 298 1.137 788 813
hsa-miR-455-3p 1,341584901 5,63E-09 4,92E-07 2,53 295 395 451 1.081 939 1.020
hsa-miR-2682-3p 1,462539389 2,16E-09 2,10E-07 2,76 69 66 56 194 177 192
hsa-miR-455-5p 1,516880996 1,08E-05 0,000553835 2,86 195 483 469 1.779 1.035 1.006
hsa-miR-137 1,569743526 1,53E-09 1,67E-07 2,97 134 165 190 654 420 495
hsa-miR-2682-5p 1,612536848 7,18E-13 1,26E-10 3,06 706 561 465 1.742 1.888 1.990
hsa-miR-34b-5p 1,618102176 0,000196521 0,007156648 3,07 5 18 9 65 39 32
hsa-miR-1245a 2,138038481 3,61E-05 0,001658394 4,40 0 1 0 10 11 15
hsa-miR-202-5p 2,203988928 1,91E-07 1,39E-05 4,61 6 15 34 170 96 116
Livello di Espressione (read_count_normalizzato)
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Part Three: Colon cancer transcriptomics analysis with 
iSmaRT.  
 
From the evidence it was decided to use a part of the series of colorectal 
carcinomas available for this project to analyze the expression patterns of the 
small RNA, in particular the piRNA, in different molecular and clinical-
pathological subclasses of these neoplasms, applying the experimental 
methodologies (smallRNA-Seq). Specifically, RNA extracts from 45 samples 
were analyzed by SmallRNA-Seq, organized in the following 4 experimental 
groups: 
 
1) 13 samples of normal tissue and 32 of tumor tissue; 
2) 4 subgroups with a variable percentage of methylation in the 
LINE-1 promoter, ie 20 samples> 60.1% (L1), 9 samples 54.1% - 
60% (L2), 9 samples 45.8% - 54% (L3) and 7 samples < 45.6% 
(L4); 
3) 16 MSI and 16 MSS samples; 
4) 8 MSI S. Lynch samples and 8 sporadic MSI. 
 
For each of the samples an average of 20 million sequences were obtained, 
the collected data allowed to identify ~ 1200 miRNA and ~ 110 piRNA 
expressed in the samples. The differential analysis (performed with iSmaRT) 
of the small RNAs among the different categories under examination (Table 
4.4 and Figure 4.27) showed a high number of miRNAs showing significant 
variations (pValue < 0.05 and FC>=|1.5|) between normal and tumor tissue, 
instead for the piRNAs the most interesting comparison was MSS Vs MSI, in 
which it was possible to identify 46 differentially expressed piRNAs (Figure 
4.28). 
 
 
Table 4.4: miRNAs and piRNAs DE in several condition of colorectal cancer. 
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Figure 4.27: Heatmap representation 
of deregulated miRNAs in tumor vs 
normal samples. 
 
 
In particular, 24 piRNA are overexpressed and 22 under-expressed in MSI 
carcinomas compared to MSS, the identified "signature" allows a good 
clasterization of the samples in the two groups and suggests a possible 
involvement of piRNAs in regulatory mechanisms of the stability of the 
genome. 
 
 
 
 
 
 
 
 
Figure 4.28: Heatmap representation 
of deregulated piRNAs in MSS vs MSI 
samples. 
 
The miRNAs and piRNAs are able to exert a post-transcriptional regulation 
of gene expression by binding to the target RNAs, in order to be able to 
identify their targets, the RNA samples of the case series have been 
sequenced by means of the Stranded total RNA protocol. For each of the 
experimental groups a "pool" was created and each library was analyzed in 
quadruplicate to obtain ~ 25 million sequences per sample. The differential 
analysis allowed to identify a large number of genes differentially expressed 
in the 9 comparisons considered (Table 4.5). The data in question are being 
developed to identify the primary targets of miRNA and piRNA and to 
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evaluate the possible existence of an inverse proportionality relationship 
between the levels of expression of the small RNA and respective targets.  
 
 
Table 4.5: mRNAs DE in several condition of colorectal cancer. 
 
In addition, Piwil1 and Piwil4, two proteins involved in the maturation and 
function of piRNAs (Figure 4.39) emerged among the genes altered in the 
different categories of colorectal carcinoma. In particular Piwil1, showed a 
variation of 47 times in the comparison between normal and tumor samples 
and more than 100 times in the comparison between sporadic MSI and Lynch 
tumors, reinforcing the hypothesis of a role of the piRNA-Piwil pathway in 
the molecular mechanisms of the tumor to the colon. 
 
 
 
 
 
Figure 4.29: Fold-change of genes 
Piwil1 and Piwil4 in several condition of 
colorectal cancer. 
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5. DISCUSSION 
 
iSmaRT is a tool made for quality controls, identification of small non-
coding RNAs, prediction of novels ones and differential expression analysis 
across multiple biological conditions, starting from small RNA-Seq datasets. 
This tool is useful to predict potential RNA target of miRNAs and piRNAs 
and to perform Reactome pathway-based analyses. The tool is not a simple 
‘collection’ of available methods and functions, but it is designed to guide the 
user during the entire analysis process. The GUI facilitates and speeds up 
usage of the different tools included. Current implementation focuses on 
simpler experimental conditions, future work will cover complex 
experimental designs. Considering the ease of use of iSmaRT and the 
goodness of the results the tools were used by ourselves to perform 
smallRNA-Seq analysis in BC cells before and after silencing the GAPT2 
protein. Thanks to the tools devised for this work, it was possible to describe 
how the landscape of sncRNAs is affected by GPAT2 silencing in triple-
negative MDA-MB-231 cells, which normally express GPAT2. 
Following the results present in the literature demonstrating that GPAT2 
participates in piRNA biogenesis in mouse germline stem cells, we 
hypothesized that this gene could also be involved in piRNA metabolism in 
somatic MDA-MB-231 cells, where piRNA synthesis was proved to be 
active. By shRNA-mediated gene silencing we showed that although GPAT2 
knockdown did not change significantly the total amounts of piRNAs, a shift 
in small RNA read length distribution was observed and specific piRNAs 
were deregulated.  
The best result is in the group of downregulated piRNAs, whose genomic 
characteristics are homogeneous and clearly distinguishable from the 
upregulated group.  
Interestingly:  
1) of these sncRNAs, 82% are present in single copy in the human 
genome, including a majority (81% - with 100% identity) located 
within the body of snoRNA genes;  
2) a high tissue-specific correlation between piRNA-snoRNA pairs was 
observed, suggesting that they are often/always co-expressed.  
 
These data refer to the mechanism of the primary biogenesis of piRNAs, in 
which piRNAs precursors are transcribed from piRNAs clusters, and then 
processed into piRNA intermediates, which subsequently are trimmed and 
modified by methylation to led to mature piRNAs (Czech et al., 2016). Since 
that snoRNA genes are 65-300 nt long, it is possible to speculate that they 
may be precursors or intermediates in the production of a certain class of 
piRNAs, and that GPAT2 is directly involved in this process. We have shown 
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that certain piRNAs are derived from snoRNAs, and that these play specific 
roles in the transcriptional and posttranscriptional regulation of gene 
expression (Zhang et al., 2015; Zhong et al., 2015). It is also worth 
mentioning that among the downregulated piRNAs it was found piR-36011.  
This piRNAs is encoded in multiple sites in the genome and each copy maps 
in one of the 14 copies of the small NF90- associated RNA A genes (SNAR-
A1 to 14). SnaRs are transcribed by RNA polymerase III and display 
restricted tissue distribution, with high expression in normal testis and 
discrete areas of the brain, and in many immortalized human cell lines 
compared to their pre-immortal counterpart (Parrott et al., 2011). snaR genes 
are predominantly located in three clusters on chromosome 19 and have been 
duplicated as part of a larger genetic element. Like snoRNA derived piRNAs, 
piR-36011 could be originated from the processing of a precursor or 
intermediate SNAR. We also searched for potential targets of the deregulated 
piRNAs, based on sequence complementarity. Several potential target genes 
were found and functional enrichment analysis revealed that the products of 
these RNAs being involved in lipid metabolism. Another relevant finding is 
that deregulated piRNAs correlate with the less tumorigenic SH phenotype. 
Moreover, several downregulated piRNAs (piR-31636, piR-57125, piR-
35548 and piR-57125) were previously found upregulated in BC cells and/or 
in breast tumors, compared to their normal tissues, whereas the upregulated 
piR-36743, piR-36318, piR-36249, piR-43772 and piR36041 were previously 
associated with a growth arrested cell phenotype. A significant association 
was found between the ‘differentiation tRNAs’ subset and the downregulated 
tRF identified in our analysis, whereas the opposite occurred with the 
upregulated ones, with a strong association to the proliferation tRNAs subset. 
Under the hypothesis that cellular tRNA pool constitutes a relevant prime 
factor that controls translation, and that variations in the expression of a 
given tRNA would affect the translation of all genes that need such tRNA, 
the increase of tRF after GPAT2 silencing could be associated with a decay 
of specific tRNAs, affecting the synthesis of specific proteins. Thus, 
deregulated tRF -considered as products of tRNA degradation- were used to 
establish a putative profile of affected proteins. Interestingly, these included 
some related to phospholipid biosynthesis and cell growth, two major 
processes previously linked with GPAT2. Of the three classes of sncRNAs 
analyzed in this study, only miRNAs display a significant variation in the 
total abundance of aligned reads, with a decrease in the SH cells, suggesting 
an impact in the overall production of miRNAs. Bioinformatics analysis 
identifies a set of potential targets for the upregulated and downregulated 
miRNAs. Target genes of miRNAs would be associated with processes 
linked to lipid biosynthesis, cell growth and proliferation. To discover if the 
deregulated miRNAs in the MDAMB-231 cells might have a role in cancer, 
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we used the YM500 database, which contains >8000 small RNA sequencing 
datasets, and integrated analysis results for various cancers miRNome 
studies. A significant overlap between the miRNAs differentially expressed 
between normal  and cancer tissues from the YM500 database and those 
found affected by GPAT2 silencing in the present study was observed. 
Furthermnore, 9 miRNAs downregulated by GPAT2 silencing have been 
found upregulated in BC, were their expression level results associated with a 
worse prognosis. Anyway, differentially expressed miRNAs identified here 
in SC vs SH cells showed a similar pattern in normal vs cancerous breast. On 
the other hand, within a cohort of PR- and ER-negative tumors miRNA 
expression was not correlated with overall survival. We speculated that there 
might be different reasons:  
1) the reduced number of cases with hormone receptor negative status 
and follow up data;  
2)  although there have been defined different molecular subtypes of 
hormone  
receptor negative tumors, particularly triple negative breast tumors, they 
usually constitute a discrete BC subgroup with a homogeneous behavior 
in respect of the prognosis and overall survival.  
 
It is worth noting that miR-454 has been found associated with poor 
prognosis in triple negative BCs (Cao et al., 2016) and miR-301 is known to 
mediate cell proliferation in invasive BC (Shi et al., 2011). Our data 
demonstrate that beyond the molecular subtype of the cell line employed, 
some of the miRNAs identified in our model could be powerful prognostic 
BC biomarkers, as was postulated in other studies, and some of them could 
constitute new ones to further validate in future studies. The specific 
characteristics of deregulated piRNAs, tRF and miRNAs strongly correlate 
with processes associated with GPAT2 in previous studies, indicating a 
specific cause-effect of GPAT2 silencing. The mechanisms by which GPAT2 
deregulate the expression of small noncoding RNAs remains unknown, but in 
this study, we show that GPAT2 modifies the abundance and length of 
specific piRNAs, tRF and miRNAs. The involvement of outer mitochondrial 
membrane proteins in primary piRNA processing was previously described 
(Ipsaro et al., 2012; Honda et al., 2013; Zhang et al., 2016). In this sense, we 
have previously postulated that GPAT2 protein contains intrinsically 
disordered regions (Rajagopalan et al., 2013); hence it is possible to speculate 
that GPAT2 could act as a scaffold protein to function in the processing of 
specific small ncRNAs that eventually control lipid biosynthesis and cell 
proliferation.  We also found a significant change in the miRNome, when 
there was an interaction between ERa and DOT1L in BCX cells treated with 
3-day or 6-day EPZ. iSmaRT was very useful for analyzing colorectal 
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samples from patients and helping us to discover a genetic signature in the 
case of normal vs tumor conditions. Thanks to the use of iSmaRT it was 
possible to analyze pancreatic cancer cells. In this thesis, the regulation 
profile of miRNA associated with ANXA1 expression in human MIA PaCa-2 
PC cells is studied. We observed the differential expression for 47 miRNA 
detected in ANXA1 KO obtained with the CRISPR / Cas9 genomic editing 
system in vitro. The analysis of the miRNoma revealed the involvement of 
ANXA1 in the progression of Pancreatic Cancer. In fact, as regards the 
down-modulated sequences in the ANXA1 KO cells, we have recognized 
miR-196a, miR-205, miR-10a and miR-10b, which are known as oncogenic 
factors, which induce proliferation, migration and invasion in different 
models of cancer (Jin et.Al, 2015). On the other hand, miR-34c, miR-455, 
miR-202, miR-137, which are upregulated in the absence of ANXA1, exert 
cancer suppression (Hagman et.Al, 2013). Subsequent analyzes have reported 
many changes that affected cytoskeletal dynamics and have influenced the 
migratory and invasive capacity of MIA PaCa-2. These cells became less 
aggressive when they lacked ANXA1 and were prone to EMT reversal. Both 
ANXA1 and miR-196a can also improve the metastatisation process. Since 
ANXA1 and miR-196a are involved in the induction of a more aggressive 
mesenchymal and phenotype (Belvedere et.Al, 2016), we evaluated cell 
migration and invasion that shows the increase in the speed of these 
processes in the presence of miR- 196a-5p to imitate. Thus, we suggest that 
the aberrant expression of miRNA, as well as ANXA1, promotes the 
progression of Pancreatic Cancer.  
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6. CONCLUSION 
 
In this PhD thesis, I described a novel tool that allows users to perform an 
accurate and complete analysis of miRNAs, piRNAs and other sncRNA 
classes from smallRNA-Seq data. Differently from other tools with similar 
functions, iSmaRT focuses mainly on piRNAs, integrating in its workflow 
two modules built for prediction of novel piRNAs and their RNA targets. 
Test performed on the data from Hoss et al. demonstrated iSmaRT potential 
in extracting novel information related to sncRNAs, and it was usefull in 
different experimental settings. Analyzing experimental data I found that 
GPAT2 silencing quantitatively and qualitatively affects the population of 
PIWI-interacting RNAs, tRNA derived fragments and miRNAs which, in 
combination, result in a more differentiated cancer cell phenotype with high 
impact on cell proliferation. The correlation between ANXA1 and specific 
miRNA sequences, such as miR-196a, adds an important element in the 
combinatorial panel of specific factors and encourages future investigations. 
In fact, both the protein and the miR-196a in Pancreatic Cancer are important 
factors that promote metastasis. Furthermore, the integration of ANXA1 into 
a more complex panel of PC-based biomarkers and differential diagnosis 
remains our central goal. The potential of iSmaRT is manifold, only in our 
case it was possible to apply it to tumor data coming from cells or patients 
and from different tumors. It has been seen how it works well with other 
diseases and the potential increases if you think about using it with other 
species. 
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